Spasticity - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018 - ResearchAndMarkets.com

DUBLIN--()--The "Spasticity - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018" report has been added to ResearchAndMarkets.com's offering.

Spasticity - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018' report provides comprehensive insights about marketed and Phase III products for Spasticity . The report includes information of marketed products including their product description, patent details, forecasted sales till 2020 & API manufacturer details by country.

This report provides a comprehensive understanding of the emerging Phase III therapies for Spasticity which can turn out to be future prospective competitors for the marketed products. It will also put light on the current market trends. Their forecasted global sales are also provided till 2020.

Scope:

  • A review of the marketed products for Spasticity including their description, route of synthesis, regulatory milestones, forecasted sales estimates till 2020 and API manufacturer details.
  • Patent information coverage of the marketed products including the patent number, holder, grant and patent expiry details
  • API manufacturers for the marketed products with location details
  • Emerging Phase III product profiles for Spasticity including product description, developmental activities, licensors & collaborators and chemical information

Key Topics Covered:

1. Report Introduction

2. Spasticity: Overview

  • Risk Factors
  • Causes
  • Symptoms
  • Pathophysiology
  • Prognosis
  • Diagnosis
  • Treatment

3. Comparative Analysis of Marketed and Emerging Products

4. Marketed Therapies

4.1. Drug 1: Company name

  • Product Description
  • Route of Synthesis
  • Mechanism of Action
  • Pharmacology
  • Pharmacodynamics
  • Pharmacokinetics
  • Adverse Reactions
  • Clinical Trials
  • Regulatory Milestones
  • Product Development Activities

4.1.1 Product Details

  • United States
  • Europe

4.1.2 Global Sales Assessment

  • Historical Global Sales
  • Forecasted Global Sales

4.1.3 Patent Details

Other marketed products in the detailed report

5. Emerging Therapies (Phase III)

5.1 Drug Name: Company Name

  • Product Description
  • Research and Development
  • Product Development Activities

5.1.1 Forecasted Global Sales

For more information about this report visit https://www.researchandmarkets.com/research/7xbw8l/spasticity?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Central Nervous System Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Central Nervous System Drugs